Aspire Biopharma Holdings, Inc.
ASBP · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 45.5% | – | – | – |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $1 | $0 | $15 | $3 |
| SG&A Expenses | $1 | $0 | $15 | $3 |
| Sales & Mktg Exp. | $0 | $0 | $0 | -$0 |
| Other Operating Expenses | $0 | $0 | $0 | -$0 |
| Operating Expenses | $1 | $1 | $16 | $3 |
| Operating Income | -$1 | -$1 | -$16 | -$3 |
| % Margin | -59,015.8% | – | – | – |
| Other Income/Exp. Net | -$1 | -$1 | -$0 | -$9 |
| Pre-Tax Income | -$2 | -$2 | -$16 | -$12 |
| Tax Expense | $0 | $0 | $0 | -$0 |
| Net Income | -$2 | -$2 | -$16 | -$12 |
| % Margin | -95,337.1% | – | – | – |
| EPS | -0.037 | -0.04 | -0.33 | -0.25 |
| % Growth | 7% | 87.8% | -32% | – |
| EPS Diluted | -0.037 | -0.04 | -0.33 | -0.25 |
| Weighted Avg Shares Out | 50 | 49 | 48 | 48 |
| Weighted Avg Shares Out Dil | 50 | 49 | 48 | 48 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1 | $1 | $0 | $1 |
| Depreciation & Amortization | $1 | $0 | $0 | $0 |
| EBITDA | $0 | -$1 | -$16 | -$11 |
| % Margin | 0% | – | – | – |